ABLYNX Receives EUR 1.2 Million Grant to Further Advance its Anti-IL-6R Programme, ALX-0061 - Gilde Healthcare

ABLYNX Receives EUR 1.2 Million Grant to Further Advance its Anti-IL-6R Programme, ALX-0061

February 19, 2010

GHENT, Belgium – Ablynx [Euronext Brussels: ABLX], announced today that it has been awarded a grant worth €1.2 million by the Flemish agency for Innovation by Science and Technology (IWT).
 
The grant supports Ablynx in accelerating the development of its Nanobody-based programme, ALX-0061, into clinical development for the treatment of autoimmune and inflammatory diseases.
 
ALX-0061 binds to the IL-6 receptor (IL-6R). It has a high potency and demonstrated a favourable pharmacodynamic (PD), pharmacokinetic (PK) and safety profile in pre-clinical testing compared with the benchmark molecule. ALX-0061 has no Fc-mediated effector function which may translate into an improved safety profile. Due to its monovalent binding to the target, it also does not have the potential to crosslink the IL-6R target which may have some benefits compared with monoclonal antibody approaches.

Edwin Moses, CEO and Chairman of Ablynx, said:

“ALX-0061 is a key programme in the Ablynx portfolio and Ablynx is on track to file an IND equivalent in Europe before the end of this year. We are delighted with IWT’s continued support of the Nanobody platform and very pleased we will also receive support for our preclinical and clinical activities related to ALX-0061. This grant is a valuable contribution to the ALX-0061 programme, which we are advancing towards clinical development. There are already four Nanobodies in the clinic, with our lead programme, ALX-0081, a novel anti-thrombotic, in Phase II since September 2009.”

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
May 21, 2024

Gilde Healthcare co-leads $100M equity financing in Karius

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and...
May 2, 2024

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024